16 September 2026 editorial review · Item
TUFF-IPC autologous adipose-derived insulin-producing cells: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-08-27T00:00:00.000Z. - Claim check: The jRCT full eligibility criteria explicitly allow ages 18–65 inclusive. Corrected “under 65” wording. This is a recruiting first-in-human study with target n=3, not evidence of efficacy.
- Programme/sponsor/conference source boundary: jRCT2063250055 — investigator-initiated FIH of autologous adipose-derived insulin-producing cells in type 1 diabetes (registry).